Adam’s Take

Adam's Take Adam Feuerstein

STAT Plus: Cassava pulled back the curtain on its Alzheimer’s study — and revealed insurmountable problems

Adam's Take Adam Feuerstein

STAT Plus: Roivant’s CEO is a star, but even a blockbuster deal can’t escape biotech’s black hole

Adam's Take Adam Feuerstein

STAT Plus: Bristol ‘take-under’ of Mirati is not so great for biotech, but company’s new cancer target has potential

Adam's Take Adam Feuerstein

STAT Plus: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind

Adam's Take Adam Feuerstein

STAT Plus: What’s behind the recent surge in Apellis’ stock price? Growing confidence in the safety of its eye treatment

Adam's Take Adam Feuerstein

STAT Plus: Anavex, maker of rare disease drug, keeps shifting the goalposts in its clinical trials

Adam's Take Adam Feuerstein

STAT Plus: A conflict of interest behind the warning on Apellis’ eye drug? The optics are not good

Adam's Take Adam Feuerstein

STAT Plus: Moonlake’s less-than-transparent data disclosures produced a cash windfall. Risks remain

Adam's Take Adam Feuerstein

STAT Plus: Instead of credible data, PDS Biotech delivers ‘results might get better, later’ promises

Adam's Take Adam Feuerstein

STAT Plus: Annexon’s trial of an eye disease drug missed by a mile. The company saw a bull’s eye

Adam's Take Adam Feuerstein

STAT Plus: Amylyx’s ALS drug launch starts strong. That could be trouble for the FDA

Adam's Take Adam Feuerstein

STAT Plus: For Cytokinetics, an FDA rejection of its heart drug would help, not hinder

Adam's Take Adam Feuerstein

STAT Plus: Once high-flying Rubius to shut down. Its flameout is a lesson for biotech

Adam's Take Adam Feuerstein

STAT Plus: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn

Adam's Take Adam Feuerstein

STAT Plus: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy

Adam's Take Adam Feuerstein

CytoDyn’s former CEO indicted for securities fraud. His misleading statements hurt patients even more than investors

Adam's Take Adam Feuerstein

STAT Plus: An Anavex study spin job sullies an otherwise spectacular Alzheimer’s conference

Adam's Take Adam Feuerstein

STAT Plus: Northwest Bio study of brain cancer vaccine still falls short

Adam's Take Adam Feuerstein

STAT Plus: With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally

Adam's Take Adam Feuerstein

STAT Plus: Not-so-happy midyear! Biotech CEOs, best and worst, and a hopeful sign of a turnaround

Adam's Take Adam Feuerstein

STAT Plus: A cautionary tale: How one biotech stock trader lost a small fortune, but emerged wiser

Adam's Take Adam Feuerstein

STAT Plus: Amylyx’s case for approval of its ALS drug isn’t ironclad. Here’s why I think it will still happen

Adam's Take Adam Feuerstein

STAT Plus: A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy

Adam's Take Adam Feuerstein

STAT Plus: It took years, but the failure of Northwest Bio’s brain cancer vaccine is now in the open

Adam's Take Adam Feuerstein

STAT Plus: A company developing a human blood substitute attempts a comeback, but IPO plans look dicey

Adam's Take Adam Feuerstein

STAT Plus: What Regeneron’s purchase of Checkmate Pharma says about the state of biotech

Adam's Take Adam Feuerstein

STAT Plus: Cel-Sci’s CEO used private call to tip off select investors about cancer drug update

Adam's Take Adam Feuerstein

STAT Plus: Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies

Adam's Take Adam Feuerstein

STAT Plus: Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent